| abstract |
the disclosure relates to fusion proteins, methods for producing fusion proteins and methods of using fusion proteins, wherein the fusion proteins comprise a functional single domain antibody (sdab) or a functional variant thereof and a cytosine protein deaminase (cd) or a functional protein variant thereof, optionally connected via a peptide ligand. the developing fusion proteins also have cd activity. the disclosure also relates to pharmaceutical compositions or formulations comprising such fusion proteins and pharmaceutically acceptable excipients, as well as medical uses of such fusion proteins. |